The approval of new medical treatments from the start of clinical trials to approval for the market can take on average over 10 years, according to most industry experts. While the process of proving new drugs to be a safe and effective treatment is a vital one, the need to accomplish this more quickly is also clear, particularly for patients waiting for life saving treatments.
Lamassu leverages innovative approaches to drive collaboration between academia and industry through translational research. Our talented team of physicians, engineers, and translational scientists have worked tirelessly to bring Lamassu to the forefront of the industry.
Our model is to identify novel therapeutics with high potential for clinical impact, having strong scientific rationale and preclinical efficacy data. We build the best scientific case, examining the mechanism, exploring additional models and indications, and identifying the most promising path forward for regulatory approval and clinical impact. Our funding has come from a combination of grants and private investors, to enable us to take advantage of non-dilutive funding where possible in order to deliver the best results for investors, without sacrificing speed or flexibility.
We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline. Our innovative model ensures that early development efforts bring products to definitive clinical testing as efficiently as possible to benefit patients, while safeguarding safety and investments.
Innovative Approach
Drive collaboration between academia and industry through translational research.
Identify Novel Therapeutics
Focus on new treatments with a high potential for clinical impact, strong scientific rationale and preclinical efficacy data.
Capitalize on Our Expertise
Use early translational research and highly qualified partner to advance clinical trials through the approval pipeline.
Lamassu Biotech leverages an innovative approach to drive collaboration between academia and industry through translational research. Our model is to identify novel therapeutics with high potential for clinical impact, having strong scientific rationale and preclinical efficacy data. We build the best scientific case, examining the mechanism, exploring additional models and indications, and identifying the most promising path forward for regulatory approval and clinical impact. Our funding has come from a combination of grants and private investors, to enable us to take advantage of non-dilutive funding where possible in order to deliver the best results for investors, without sacrificing speed or flexibility.
We capitalize on our expertise in early translational research to bring products to Phase I/II and partner with clinical and commercial development specialists to advance clinical trials through the approval pipeline. Our innovative model ensures that early development efforts bring products to definitive clinical testing as efficiently as possible to benefit patients, while safeguarding safety and investments.
Lamassu’s SA53 MDM2 inhibitor is a novel therapeutic that targets p53 wild-type sarcomas, malignant tumors of connective or non-epithelial tissue. SA53 has demonstrated remarkable potency, efficacy and safety in preclinical models, positioning it for an Investigational New Drug (IND) submission. This innovative approach offers promising prospects for addressing chemo-resistant cancer and presents a significant pathway for advancing cancer care. The proposed therapy aims to trigger the body’s natural defense mechanism, p53 by blocking MDM2, a protein that deactivates p53 and contributes to treatment resistance
Lamassu’s RABI-767 is a novel small molecule therapy for acute pancreatitis, a condition that results in more than 330,000 hospital admissions per year in the U.S., and the death of approximately five percent of patients suffering from the disease. RABI-767 was developed at Mayo Clinic by leading scientists, and has profound preclinical efficacy to completely mitigate mortality and morbidity associated with severe acute pancreatitis.
Learn More
PARTNERS
